ArticleWorld journal of gastrointestinal oncology2023
Incidence and prevalence of gastric neuroendocrine tumors in patients with chronic atrophic autoimmune gastritis.
Article in World journal of gastrointestinal oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- The role of autoimmune gastritis in gastric cancer risk: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- A systematic review of gastritis as an immune-related adverse event in clinical interventions.Human vaccines & immunotherapeutics · 2024Pooled it
- Autoimmune gastritis: emerging insights and clinical management.Nature reviews. Gastroenterology & hepatology · 2026Review
- Oxyntic Gland Intraepithelial T Lymphocytes as Progression Marker of Potential Autoimmune Gastritis.Clinical and translational gastroenterology · 2026Article
- Autoimmune gastritis potentiates polypoid nodule scar formation after endoscopic resection: implications for risk-stratified surveillance.Surgical endoscopy · 2026Article
- Characterization of neuroendocrine cell hyperplasia in autoimmune gastritis: improving H&E-based diagnosis through systematic training.BMC gastroenterology · 2026Article
- Factors associated with type 1 gastric neuroendocrine tumor occurrence in autoimmune atrophic gastritis: insights from a real-world cohort.Frontiers in endocrinology · 2026Article
- Response to Dell'Unto et al.The American journal of gastroenterology · 2025Article
- Autoimmune gastritis: clinical and histological study in a Peruvian population.BMC gastroenterology · 2025Article
- Pediatric autoimmune gastritis: An international, multicentric study.Journal of pediatric gastroenterology and nutrition · 2025Article
- Review
- Gastric neuroendocrine tumors: A review of pathology and updated roadmap to surgical management.World journal of clinical oncology · 2025Review
- Helicobacter pylori VacA-induced gastric mucosal atrophy: a comparative analysis with other forms of atrophic gastritis.Journal of molecular histology · 2025Article
- Autoimmune Gastritis: Unveiling the Mystery.The Korean journal of helicobacter and upper gastrointestinal research · 2025Review
- Last decade of advances in gastric neuroendocrine tumors: Innovations, challenges, and future directions.World journal of clinical oncology · 2025Article
- A Multitask Network for the Diagnosis of Autoimmune Gastritis.Journal of imaging · 2025Article
- Immunological and clinical overlap between autoimmune gastritis and autoimmune liver diseases: a prospective cohort study.Frontiers in immunology · 2025Article
- Gastric Neuroendocrine Tumors and Pernicious Anemia: A Case Report and Literature Review.Cureus · 2024Article
- Autoimmune gastritis studies and gastric cancer: True renaissance or bibliometric illusion.World journal of gastroenterology · 2024Review
- Autoimmune Gastritis and Hypochlorhydria: Known Concepts from a New Perspective.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of type I gastric neuroendocrine neoplasms (gNENs) has increased significantly over the past 50 years. Although autoimmune gastritis (AIG) increases the likelihood of developing gNENs, the exact incidence and prevalence of this association remain unclear.
aimTo evaluate the incidence and prevalence of type I gNENs in a cohort of patients with a histological diagnosis of AIG.
methodsPatients with a histological diagnosis of AIG were enrolled between October 2020 and May 2022. Circulating levels of CgA and gastrin were assessed at enrollment. Included patients underwent regular endoscopic follow-up to detect gastric neoplastic lesions, enterochromaffin-like (ECL) cell hyperplasia, and the development of gNEN.
resultsWe included 176 patients [142 women (80.7%), median age 64 years, interquartile range (IQR) 53-71 years] diagnosed with AIG between January 1990 and June 2022. At enrollment. One hundred and sixteen patients (65.9%) had ECL hyperplasia, of whom, 29.5% had simple/linear, 30.7% had micronodular, and 5.7% had macronodular type. The median follow-up time was 5 (3-7.5) years. After 1032 person-years, 33 patients developed a total of 50 type I gNENs, with an incidence rate of 0.057 person-years, corresponding to an annual cumulative incidence of 5.7%. Circulating CgA levels did not significantly differ between AIG patients who developed gNENs and those who did not. Conversely, gastrin levels were significantly higher in AIG patients who developed gNENs [median 992 pg/mL IQR = 449-1500
conclusionType I gNENs are a significant complication in AIG. Gastrin's low diagnostic accuracy prevents it from serving as a marker for early diagnosis. Effective strategies for early detection and treatment are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.